The proposal was cleared in the meeting of the Cabinet Committee on Economic Affairs (CCEA) headed by Prime Minister Narendra Modi.
"The Cabinet Committee on Economic Affairs today gave its approval to the proposal of M/s Lupin Limited for increase in aggregate limit of investment by FIIs and their sub-accounts registered with SEBI, from 33 per cent to 49 percent," an official statement said.
"The approval would result in foreign investment of Rs 6,099 crore (approximately) in the country," it added.
Mumbai-based Lupin is a significant player in the various therapeutic segments including cardiovascular, diabetology, asthma, paediatric and anti-infectives.
It its fifth largest and fastest growing top 5 generics player in the US market and third largest Indian pharmaceutical company by sales.
For the financial year ended March 2014, Lupin's consolidated revenues and profit after tax were Rs 11,086.6 crore and Rs 1,836.4 crore respectively.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
